Z.M.D Group operates under two companies fully collaborated:
Z.M.D Diagnostics Ltd – develops and commercializes an innovative early cancer detection and disease management platform.
Z.M.D Medical Ltd – develops and commercializes a therapeutic remedy to cure cancer of all types using the immune system.
Z.M.D Diagnostics Ltd is developing an innovative early cancer detection and disease management platform based on its revolutionary discovery that cancer causes alterations in the function and composition of intestinal microflora in a quantifiable and measurable manner.
The company is focusing on establishing two main products: an accurate early diagnosis of cancer for hospital use and indicative examination for home to monitor the effectiveness of anticancer treatment
Z.M.D Medical Ltd develops and commercializes a therapeutic remedy to cure cancer of all types using the immune system.
Z.M.D Medical has set a goal to produce probiotic preparations to rehabilitate distressed colon microflora in order to eliminate cancer from patient´s immune systems and help it recover.
Z.M.D Group was established in August 2014. Z.M.D Group operates under two companies fully collaborated.
Z.M.D Diagnostics Ltd develops and commercializes an innovative early cancer detection and disease management platform based on its revolutionary discovery that cancer causes alterations in the function and composition of intestinal microflora in a quantifiable and measurable manner. To date, Z.M.D has developed a proprietary bioassay based on its core technology that has demonstrated effective clinical outcomes in vitro and during preliminary clinical studies. The Company is currently finalizing prototype development for its first product that will detect cancer of any kind and localization early.
Z.M.D Medical Ltd is a sister company of Z.M.D Diagnostics, develops and commercializes a therapeutic remedy to cure cancer of all types using the immune system.
Z.M.D Group expects a platform of product opportunities, both diagnostic and therapeutic, to be derived from its core technology in years to come.
